Dear Colleague Letters
Updated January 7, 2021
2020
- CDC Releases “Reported Tuberculosis in the United States, 2019”
- Landmark TB Trial Identifies Shorter-Course Treatment Regimen
- Update on Rifamycin Issues – September 11, 2020
- Print Copies Available for Order- UPDATED Latent Tuberculosis Infection: A Guide for Primary Health Care Providers
- Rifampin Availability and Discontinuation of Sanofi-Aventis Rifampin Products – August 18, 2020
- Maintaining Essential Components of TB Control Programs – July 30, 2020
- Reported Rifapentine Impurity – June 18, 2020
- A Letter from Dr. Robert Redfield, CDC Director on World TB Day
PDF Versionpdf icon - CDC World TB Day Resources – March 24, 2020
- 2020 TB Elimination Champions
- CDC and the National Tuberculosis Controllers Association Release New Guidelines for Treatment of Latent TB Infection
2019
- NEW Drug-Resistant TB Treatment Guidelines and CDC Antibiotic Resistance Threats Report
- CDC Releases “Reported Tuberculosis in the United States, 2018
- Nationwide Shortage of Tuberculin Skin Test Antigens: CDC Recommendations for Patient Care and Public Health Practice – June 7, 2019
- CDC and the National Tuberculosis Controllers Association Releases Updated Recommendations for Tuberculosis Screening, Testing and Treatment for Health Care Personnel – May 16, 2019
- World TB Day – March 24, 2019
Page last reviewed: April 9, 2019
Content source: Division of Tuberculosis Elimination